Novel insight into glucagon receptor action: Lessons from knockout and transgenic mouse models

P. M. Vuguin, Maureen J. Charron

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Using knockout and transgenic technology, genetically modified animal models allowed us to understand the role of glucagon signalling in metabolism. Mice with a global deletion of the glucagon receptor gene (Gcgr) were designed using gene targeting. The phenotype of Gcgr-/-mouse provided important clues about the role of Gcgr in foetal growth, pancreatic development and glucose and lipid homeostasis. The lack of Gcgr activation was associated with: (i) hypoglycaemic pregnancies, poor foetal growth and increased foetal-neonatal demise; (ii) altered cytoarchitecture of pancreatic islets; (iii) altered glucose, lipid and hormonal milieu; (iv) reduced gastric emptying; (v) altered body composition and protection from diet-induced obesity; (vi) altered energy state; (vii) impaired hepatocyte survival; (viii) altered metabolic response to prolonged fasting and exercise and (ix) prevented development of diabetes in insulin-deficient mice. In contrast, mice overexpressing the Gcgr on pancreatic β-cells displayed an increase insulin secretion, pancreatic insulin content and β-cell mass, and partially protected against hyperglycaemia and impaired glucose tolerance when fed a high-fat diet. These findings suggest that glucagon signalling plays a significant role in the regulation of glucose and lipid homeostasis. Treatment options designed to block Gcgr activation may have negative implications in the treatment of diabetes.

Original languageEnglish (US)
Pages (from-to)144-150
Number of pages7
JournalDiabetes, Obesity and Metabolism
Volume13
Issue numberSUPPL. 1
DOIs
StatePublished - Oct 2011

Fingerprint

Glucagon Receptors
Knockout Mice
Transgenic Mice
Insulin
Fetal Development
Glucagon
Lipids
Glucose
Transcriptional Activation
Genes
Homeostasis
Genetically Modified Animals
Fetal Death
Glucose Intolerance
Gene Targeting
Gastric Emptying
High Fat Diet
Body Composition
Islets of Langerhans
Growth and Development

Keywords

  • Diabetes
  • Gcgr knockout mouse model
  • Glucagon
  • Glucagon signalling
  • Hypoglycaemia
  • Islets
  • Pancreas

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Novel insight into glucagon receptor action : Lessons from knockout and transgenic mouse models. / Vuguin, P. M.; Charron, Maureen J.

In: Diabetes, Obesity and Metabolism, Vol. 13, No. SUPPL. 1, 10.2011, p. 144-150.

Research output: Contribution to journalArticle

@article{d6448d4d1c914760b7bb0c0790669355,
title = "Novel insight into glucagon receptor action: Lessons from knockout and transgenic mouse models",
abstract = "Using knockout and transgenic technology, genetically modified animal models allowed us to understand the role of glucagon signalling in metabolism. Mice with a global deletion of the glucagon receptor gene (Gcgr) were designed using gene targeting. The phenotype of Gcgr-/-mouse provided important clues about the role of Gcgr in foetal growth, pancreatic development and glucose and lipid homeostasis. The lack of Gcgr activation was associated with: (i) hypoglycaemic pregnancies, poor foetal growth and increased foetal-neonatal demise; (ii) altered cytoarchitecture of pancreatic islets; (iii) altered glucose, lipid and hormonal milieu; (iv) reduced gastric emptying; (v) altered body composition and protection from diet-induced obesity; (vi) altered energy state; (vii) impaired hepatocyte survival; (viii) altered metabolic response to prolonged fasting and exercise and (ix) prevented development of diabetes in insulin-deficient mice. In contrast, mice overexpressing the Gcgr on pancreatic β-cells displayed an increase insulin secretion, pancreatic insulin content and β-cell mass, and partially protected against hyperglycaemia and impaired glucose tolerance when fed a high-fat diet. These findings suggest that glucagon signalling plays a significant role in the regulation of glucose and lipid homeostasis. Treatment options designed to block Gcgr activation may have negative implications in the treatment of diabetes.",
keywords = "Diabetes, Gcgr knockout mouse model, Glucagon, Glucagon signalling, Hypoglycaemia, Islets, Pancreas",
author = "Vuguin, {P. M.} and Charron, {Maureen J.}",
year = "2011",
month = "10",
doi = "10.1111/j.1463-1326.2011.01447.x",
language = "English (US)",
volume = "13",
pages = "144--150",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Novel insight into glucagon receptor action

T2 - Lessons from knockout and transgenic mouse models

AU - Vuguin, P. M.

AU - Charron, Maureen J.

PY - 2011/10

Y1 - 2011/10

N2 - Using knockout and transgenic technology, genetically modified animal models allowed us to understand the role of glucagon signalling in metabolism. Mice with a global deletion of the glucagon receptor gene (Gcgr) were designed using gene targeting. The phenotype of Gcgr-/-mouse provided important clues about the role of Gcgr in foetal growth, pancreatic development and glucose and lipid homeostasis. The lack of Gcgr activation was associated with: (i) hypoglycaemic pregnancies, poor foetal growth and increased foetal-neonatal demise; (ii) altered cytoarchitecture of pancreatic islets; (iii) altered glucose, lipid and hormonal milieu; (iv) reduced gastric emptying; (v) altered body composition and protection from diet-induced obesity; (vi) altered energy state; (vii) impaired hepatocyte survival; (viii) altered metabolic response to prolonged fasting and exercise and (ix) prevented development of diabetes in insulin-deficient mice. In contrast, mice overexpressing the Gcgr on pancreatic β-cells displayed an increase insulin secretion, pancreatic insulin content and β-cell mass, and partially protected against hyperglycaemia and impaired glucose tolerance when fed a high-fat diet. These findings suggest that glucagon signalling plays a significant role in the regulation of glucose and lipid homeostasis. Treatment options designed to block Gcgr activation may have negative implications in the treatment of diabetes.

AB - Using knockout and transgenic technology, genetically modified animal models allowed us to understand the role of glucagon signalling in metabolism. Mice with a global deletion of the glucagon receptor gene (Gcgr) were designed using gene targeting. The phenotype of Gcgr-/-mouse provided important clues about the role of Gcgr in foetal growth, pancreatic development and glucose and lipid homeostasis. The lack of Gcgr activation was associated with: (i) hypoglycaemic pregnancies, poor foetal growth and increased foetal-neonatal demise; (ii) altered cytoarchitecture of pancreatic islets; (iii) altered glucose, lipid and hormonal milieu; (iv) reduced gastric emptying; (v) altered body composition and protection from diet-induced obesity; (vi) altered energy state; (vii) impaired hepatocyte survival; (viii) altered metabolic response to prolonged fasting and exercise and (ix) prevented development of diabetes in insulin-deficient mice. In contrast, mice overexpressing the Gcgr on pancreatic β-cells displayed an increase insulin secretion, pancreatic insulin content and β-cell mass, and partially protected against hyperglycaemia and impaired glucose tolerance when fed a high-fat diet. These findings suggest that glucagon signalling plays a significant role in the regulation of glucose and lipid homeostasis. Treatment options designed to block Gcgr activation may have negative implications in the treatment of diabetes.

KW - Diabetes

KW - Gcgr knockout mouse model

KW - Glucagon

KW - Glucagon signalling

KW - Hypoglycaemia

KW - Islets

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=79961176667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961176667&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2011.01447.x

DO - 10.1111/j.1463-1326.2011.01447.x

M3 - Article

C2 - 21824268

AN - SCOPUS:79961176667

VL - 13

SP - 144

EP - 150

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - SUPPL. 1

ER -